Preoperative treatment of locally advanced rectal cancer
Schrag D, Shi Q, Weiser MR, Gollub MJ, Saltz LB, Musher BL et al.
N Engl J Med 2023; 389: 322-334.
Some 1194 patients with stage T2 or T3 rectal cancer were randomized to neoadjuvant chemoradiotherapy (standard care) or chemotherapy alone. Five-year disease-free survival was 80.8 per cent after chemotherapy alone compared to 78.6 per cent after standard care, P=0.005 for noninferiority. Overall survival rates were similar.
Comment: This is important as it could change standard care. Surgeons have never been keen to operate on recently irradiated tissue.
18 October 2023Read paper
Part of the charitable activity of the Society, BJS Academy is an online educational resource for current and future surgeons.
The Academy is comprised of five distinct sections: Continuing surgical education, Young BJS, Cutting edge, Scientific surgery and Surgical news. Although the majority of this is open access, additional content is available to BJS subscribers and strategic partners.